Sequential Skin will join as a resident company of Johnson & Johnson Innovation, JLABS, a premier life science incubator program this November. JLABS is a global network of open innovation ecosystems, enabling and empowering innovators to create and accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps entrepreneurs in pharmaceutical, medical device, consumer, and health tech bring healthcare solutions to patients and consumers.
Joining the Johnson & Johnson Innovation, JLABS ecosystem, will further enable Sequential Skin to understand the biology of the skin, and determine how genetics, epigenetics and the skin microbiome play a crucial role in both skin health and skin disease.